| Record Information | 
|---|
| Version | 5.0 | 
|---|
| Status | Detected but not Quantified | 
|---|
| Creation Date | 2012-09-06 15:16:49 UTC | 
|---|
| Update Date | 2022-03-07 02:51:35 UTC | 
|---|
| HMDB ID | HMDB0014332 | 
|---|
| Secondary Accession Numbers |  | 
|---|
| Metabolite Identification | 
|---|
| Common Name | Lorazepam | 
|---|
| Description | Lorazepam is only found in individuals that have used or taken this drug. It is a benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent. [PubChem]Lorazepam binds to an allosteric site on GABA-A receptors, which are pentameric ionotropic receptors in the CNS. Binding potentiates the effects of the inhibitory neurotransmitter GABA, which upon binding opens the chloride channel in the receptor, allowing chloride influx and causing hyperpolerization of the neuron. | 
|---|
| Structure | OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2 InChI=1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)  | 
|---|
| Synonyms | | Value | Source | 
|---|
 | Ativan | Kegg |  | (+/-)-lorazepam | HMDB |  | O-Chlorooxazepam | HMDB |  | O-Chloroxazepam | HMDB |  | AHP brand OF lorazepam | MeSH, HMDB |  | apo Lorazepam | MeSH, HMDB |  | Llorens brand OF lorazepam | MeSH, HMDB |  | Lorazepam ahp brand | MeSH, HMDB |  | Lorazepam baxter brand | MeSH, HMDB |  | Lorazepam medical | MeSH, HMDB |  | Lorazepam medix brand | MeSH, HMDB |  | Lorazepam wyeth brand | MeSH, HMDB |  | Lorazepam neuraxpharm brand | MeSH, HMDB |  | Lorazepam ratiopharm brand | MeSH, HMDB |  | Medix brand OF lorazepam | MeSH, HMDB |  | novo Lorazem | MeSH, HMDB |  | novo-Lorazem | MeSH, HMDB |  | Novopharm brand OF lorazepam | MeSH, HMDB |  | Lorazep von CT | MeSH, HMDB |  | Neuraxpharm brand OF lorazepam | MeSH, HMDB |  | Ratiopharm brand OF lorazepam | MeSH, HMDB |  | Dolorgiet brand OF lorazepam | MeSH, HMDB |  | Duralozam | MeSH, HMDB |  | Laubeel | MeSH, HMDB |  | Lorazepam apotex brand | MeSH, HMDB |  | Lorazepam desitin brand | MeSH, HMDB |  | Lorazepam CT-arzneimittel brand | MeSH, HMDB |  | Lorazepam-ratiopharm | MeSH, HMDB |  | Merck dura brand OF lorazepam | MeSH, HMDB |  | Nu-loraz | MeSH, HMDB |  | Riemser brand OF lorazepam | MeSH, HMDB |  | Serra pamies brand OF lorazepam | MeSH, HMDB |  | Sinestron | MeSH, HMDB |  | Temesta | MeSH, HMDB |  | Tolid | MeSH, HMDB |  | Wyeth, orfidal | MeSH, HMDB |  | CT Arzneimittel brand OF lorazepam | MeSH, HMDB |  | ApoLorazepam | MeSH, HMDB |  | Baxter brand OF lorazepam | MeSH, HMDB |  | Idalprem | MeSH, HMDB |  | Lorazepam dolorgiet brand | MeSH, HMDB |  | Lorazepam medical brand | MeSH, HMDB |  | Lorazepam novartis brand | MeSH, HMDB |  | Lorazepam riemser brand | MeSH, HMDB |  | Lorazepam ratiopharm | MeSH, HMDB |  | Lorazepam-neuraxpharm | MeSH, HMDB |  | Medical brand OF lorazepam | MeSH, HMDB |  | Medical, lorazepam | MeSH, HMDB |  | NovoLorazem | MeSH, HMDB |  | Nu loraz | MeSH, HMDB |  | Orfidal wyeth | MeSH, HMDB |  | Somagerol | MeSH, HMDB |  | apo-Lorazepam | MeSH, HMDB |  | Apotex brand OF lorazepam | MeSH, HMDB |  | Desitin brand OF lorazepam | MeSH, HMDB |  | Donix | MeSH, HMDB |  | Durazolam | MeSH, HMDB |  | Lorazepam llorens brand | MeSH, HMDB |  | Lorazepam novopharm brand | MeSH, HMDB |  | Lorazepam nu-pharm brand | MeSH, HMDB |  | Lorazepam neuraxpharm | MeSH, HMDB |  | Novartis brand OF lorazepam | MeSH, HMDB |  | Nu pharm brand OF lorazepam | MeSH, HMDB |  | Nu-pharm brand OF lorazepam | MeSH, HMDB |  | NuLoraz | MeSH, HMDB |  | Sedicepan | MeSH, HMDB |  | Wyeth brand OF lorazepam | MeSH, HMDB |  | CT-Arzneimittel brand OF lorazepam | MeSH, HMDB |  | Von CT, lorazep | MeSH, HMDB |  
  | 
|---|
| Chemical Formula | C15H10Cl2N2O2 | 
|---|
| Average Molecular Weight | 321.158 | 
|---|
| Monoisotopic Molecular Weight | 320.011932988 | 
|---|
| IUPAC Name | 7-chloro-5-(2-chlorophenyl)-3-hydroxy-2,3-dihydro-1H-1,4-benzodiazepin-2-one | 
|---|
| Traditional Name | lorazepam | 
|---|
| CAS Registry Number | 846-49-1 | 
|---|
| SMILES | OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2  | 
|---|
| InChI Identifier | InChI=1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)  | 
|---|
| InChI Key | DIWRORZWFLOCLC-UHFFFAOYSA-N | 
|---|
| Chemical Taxonomy | 
|---|
| Description |  Belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine. | 
|---|
| Kingdom | Organic compounds   | 
|---|
| Super Class | Organoheterocyclic compounds   | 
|---|
| Class | Benzodiazepines   | 
|---|
| Sub Class | 1,4-benzodiazepines   | 
|---|
| Direct Parent | 1,4-benzodiazepines   | 
|---|
| Alternative Parents |  | 
|---|
| Substituents | - 1,4-benzodiazepine
 
- Alpha-amino acid or derivatives
 
- Chlorobenzene
 
- Halobenzene
 
- Aryl chloride
 
- Aryl halide
 
- Monocyclic benzene moiety
 
- Benzenoid
 
- Carboxamide group
 
- Ketimine
 
- Secondary carboxylic acid amide
 
- Lactam
 
- Alkanolamine
 
- Carboxylic acid derivative
 
- Azacycle
 
- Organic 1,3-dipolar compound
 
- Propargyl-type 1,3-dipolar organic compound
 
- Imine
 
- Organic oxygen compound
 
- Organic nitrogen compound
 
- Hydrocarbon derivative
 
- Carbonyl group
 
- Organic oxide
 
- Organopnictogen compound
 
- Organooxygen compound
 
- Organohalogen compound
 
- Organochloride
 
- Organonitrogen compound
 
- Aromatic heteropolycyclic compound
 
  | 
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds | 
|---|
| External Descriptors | Not Available | 
|---|
| Ontology | 
|---|
| Physiological effect | Not Available | 
|---|
| Disposition |  | 
|---|
| Process | Not Available | 
|---|
| Role | Not Available | 
|---|
| Physical Properties | 
|---|
| State | Solid | 
|---|
| Experimental Molecular Properties | | Property | Value | Reference | 
|---|
 | Melting Point | 166 - 168 °C | Not Available |  | Boiling Point | Not Available | Not Available |  | Water Solubility | 0.018 g/L | Not Available |  | LogP | 3.5 | Not Available |  
  | 
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections| Adduct Type | Data Source | CCS Value (Å2) | Reference | 
|---|
 | [M+H]+ | CBM | 165.8 | 30932474   |  
  | 
|---|
| Predicted Molecular Properties |  | 
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference | 
|---|
 | Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.17 minutes | 32390414   |  | Predicted by Siyang on May 30, 2022 | 15.0123 minutes | 33406817   |  | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.16 minutes | 32390414   |  | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 29.8 seconds | 40023050   |  
 Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference | 
|---|
 | Lorazepam,1TMS,isomer #1 | C[Si](C)(C)OC1N=C(C2=CC=CC=C2Cl)C2=CC(Cl)=CC=C2NC1=O | 2753.9 | Semi standard non polar | 33892256   |  | Lorazepam,1TMS,isomer #2 | C[Si](C)(C)N1C(=O)C(O)N=C(C2=CC=CC=C2Cl)C2=CC(Cl)=CC=C21 | 2571.4 | Semi standard non polar | 33892256   |  | Lorazepam,2TMS,isomer #1 | C[Si](C)(C)OC1N=C(C2=CC=CC=C2Cl)C2=CC(Cl)=CC=C2N([Si](C)(C)C)C1=O | 2591.1 | Semi standard non polar | 33892256   |  | Lorazepam,2TMS,isomer #1 | C[Si](C)(C)OC1N=C(C2=CC=CC=C2Cl)C2=CC(Cl)=CC=C2N([Si](C)(C)C)C1=O | 2612.5 | Standard non polar | 33892256   |  | Lorazepam,2TMS,isomer #1 | C[Si](C)(C)OC1N=C(C2=CC=CC=C2Cl)C2=CC(Cl)=CC=C2N([Si](C)(C)C)C1=O | 3526.9 | Standard polar | 33892256   |  | Lorazepam,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1N=C(C2=CC=CC=C2Cl)C2=CC(Cl)=CC=C2NC1=O | 2909.3 | Semi standard non polar | 33892256   |  | Lorazepam,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N1C(=O)C(O)N=C(C2=CC=CC=C2Cl)C2=CC(Cl)=CC=C21 | 2785.7 | Semi standard non polar | 33892256   |  | Lorazepam,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1N=C(C2=CC=CC=C2Cl)C2=CC(Cl)=CC=C2N([Si](C)(C)C(C)(C)C)C1=O | 2932.6 | Semi standard non polar | 33892256   |  | Lorazepam,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1N=C(C2=CC=CC=C2Cl)C2=CC(Cl)=CC=C2N([Si](C)(C)C(C)(C)C)C1=O | 3001.7 | Standard non polar | 33892256   |  | Lorazepam,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1N=C(C2=CC=CC=C2Cl)C2=CC(Cl)=CC=C2N([Si](C)(C)C(C)(C)C)C1=O | 3593.5 | Standard polar | 33892256   |  
  | 
|---|
 | GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View | 
|---|
 | Experimental GC-MS | GC-MS Spectrum - Lorazepam EI-B (Non-derivatized) | splash10-009i-6791000000-942b7493f1e9fc3d12be | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum |  | Experimental GC-MS | GC-MS Spectrum - Lorazepam EI-B (Non-derivatized) | splash10-009i-6791000000-942b7493f1e9fc3d12be | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum |  | Predicted GC-MS | Predicted GC-MS Spectrum - Lorazepam GC-MS (Non-derivatized) - 70eV, Positive | splash10-004u-0290000000-b7b54d40e4a40249fc2d | 2017-09-01 | Wishart Lab | View Spectrum |  | Predicted GC-MS | Predicted GC-MS Spectrum - Lorazepam GC-MS (1 TMS) - 70eV, Positive | splash10-00b9-9235000000-97d74a04d7ec48e6bb28 | 2017-10-06 | Wishart Lab | View Spectrum |  | Predicted GC-MS | Predicted GC-MS Spectrum - Lorazepam GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |  | Predicted GC-MS | Predicted GC-MS Spectrum - Lorazepam GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |  | Predicted GC-MS | Predicted GC-MS Spectrum - Lorazepam GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum |  | Predicted GC-MS | Predicted GC-MS Spectrum - Lorazepam GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum |  | Predicted GC-MS | Predicted GC-MS Spectrum - Lorazepam GC-MS (TBDMS_1_2) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum |  | MS | Mass Spectrum (Electron Ionization) | splash10-002r-4981000000-a567f7beb26ee18d061c | 2014-09-20 | Not Available | View Spectrum |  
 MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View | 
|---|
 | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lorazepam LC-ESI-qTof , Positive-QTOF | splash10-00b9-0298000000-986499cda13643ef7d85 | 2017-09-14 | HMDB team, MONA | View Spectrum |  | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , negative-QTOF | splash10-001i-0091000000-04730f82e569df7febdd | 2017-09-14 | HMDB team, MONA | View Spectrum |  | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , negative-QTOF | splash10-001i-0390000000-dd63d93f2fa81cbb5928 | 2017-09-14 | HMDB team, MONA | View Spectrum |  | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , negative-QTOF | splash10-0udi-0930000000-3ecf1f2f10049a3cfee2 | 2017-09-14 | HMDB team, MONA | View Spectrum |  | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , negative-QTOF | splash10-0udi-0910000000-95d23a9a121bf45ef8bf | 2017-09-14 | HMDB team, MONA | View Spectrum |  | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , negative-QTOF | splash10-0udi-0900000000-cdbe26e697f259770c28 | 2017-09-14 | HMDB team, MONA | View Spectrum |  | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , negative-QTOF | splash10-0udi-0900000000-4046d54b4dd9bf7968be | 2017-09-14 | HMDB team, MONA | View Spectrum |  | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , negative-QTOF | splash10-001i-0091000000-abaf38ed3aa6e7d51245 | 2017-09-14 | HMDB team, MONA | View Spectrum |  | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lorazepam LC-ESI-QTOF , positive-QTOF | splash10-052b-9000000000-dda683413448d0461123 | 2017-09-14 | HMDB team, MONA | View Spectrum |  | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , positive-QTOF | splash10-00di-0009000000-53bbea620bd1e8b49eb3 | 2017-09-14 | HMDB team, MONA | View Spectrum |  | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , positive-QTOF | splash10-0fb9-0095000000-793565a97e3afc2ce858 | 2017-09-14 | HMDB team, MONA | View Spectrum |  | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , positive-QTOF | splash10-004i-0090000000-41097b8a64363c5e2f94 | 2017-09-14 | HMDB team, MONA | View Spectrum |  | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , positive-QTOF | splash10-004i-0290000000-a0694111a3943eca2b53 | 2017-09-14 | HMDB team, MONA | View Spectrum |  | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , positive-QTOF | splash10-004i-0690000000-5a4728cb7e2473fc6b3c | 2017-09-14 | HMDB team, MONA | View Spectrum |  | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , positive-QTOF | splash10-01rf-0940000000-39d041fbab4fb67a5c41 | 2017-09-14 | HMDB team, MONA | View Spectrum |  | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lorazepam  , positive-QTOF | splash10-00b9-0298000000-986499cda13643ef7d85 | 2017-09-14 | HMDB team, MONA | View Spectrum |  | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , positive-QTOF | splash10-00b9-0196000000-2e53b39b27c66ec73fd2 | 2017-09-14 | HMDB team, MONA | View Spectrum |  | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lorazepam  30V, Positive-QTOF | splash10-004i-0090000000-4b5b5c3dfb63873733bf | 2021-09-20 | HMDB team, MONA | View Spectrum |  | Experimental LC-MS/MS | LC-MS/MS Spectrum - Lorazepam  -1V, Positive-QTOF | splash10-052b-9000000000-dda683413448d0461123 | 2021-09-20 | HMDB team, MONA | View Spectrum |  | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lorazepam  10V, Positive-QTOF | splash10-00di-0029000000-ee07ef7d365d458f9d34 | 2016-08-03 | Wishart Lab | View Spectrum |  | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lorazepam  20V, Positive-QTOF | splash10-00di-0239000000-5c6908c1fea1275fb874 | 2016-08-03 | Wishart Lab | View Spectrum |  | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lorazepam  40V, Positive-QTOF | splash10-0zfr-1981000000-3701b2aca45eeea63d62 | 2016-08-03 | Wishart Lab | View Spectrum |  | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lorazepam  10V, Negative-QTOF | splash10-014i-0009000000-58ac02858c22990ff345 | 2016-08-03 | Wishart Lab | View Spectrum |  | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lorazepam  20V, Negative-QTOF | splash10-014i-0339000000-f3e5eccf9c4e49dcfbcf | 2016-08-03 | Wishart Lab | View Spectrum |  | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lorazepam  40V, Negative-QTOF | splash10-000i-3490000000-6b141b0755058109e70a | 2016-08-03 | Wishart Lab | View Spectrum |  
  | 
|---|